Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 54-60

  Lely, A Titia ^a   van der Kleij, Frank G H ^b   Kistemaker, Taco J ^a   Apperloo, Alfred J ^c   de Jong, Paul E ^a   de Zeeuw, Dick ^d   Navis, Gerjan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Scheper Ziekenhuis   (Netherlands)

^c CPRLab   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION;

ADULT; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; PREDICTIVE VALUE OF TESTS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC;

EID: 38749097064     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01450307     Document Type: Article

References (21)

1. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884, 1994
2. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
4. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863, 1997
5. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339-343, 1992
6. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309: 833-837, 1994
7. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42: 452-458, 1992
8. Mitch WE, Walser M, Buffington GA, Lemann J Jr: A simple method of estimating progression of chronic renal failure. Lancet 2: 1326-1328, 1976
9. van Essen GG, Rensma. PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347: 94-95, 1996
10. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63: S58-S62, 1997
11. Shanmugam V, Sell KW, Saha BK: Mistyping ACE heterozygotes. PCR Methods Appl 3: 120-121, 1993
12. Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim. GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM: Importance of baseline distribution of proteinuria. in renal outcomes trials: Lessons from the Reduction of Endpoints, in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. J Am Soc Nephrol 16: 1775-1780, 2005
13. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 57: 274-281, 2000
14. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN). J Am Soc Nephrol 11: 88-96, 2000
15. Ha SK, Yong Lee S, Su Park H, Ho Shin J, Jung Kim S, Hun Kim D, Rae Kim K, Yung Lee H, Suk Han D: ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 15: 1617-1623, 2000
16. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Rodger RS, Junor BJ, Briggs JD, Connell JM, Jardine AG: Polymorphisms, in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345: 1540-1542, 1995
17. Hunley TE, Julian BA, Phillips JA III, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49: 571-577, 1996
18. McLaughlin K, Harden P, Ueda S, Boulton-Jones JM, Connell J, Jardine A: The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension 28: 912-915, 1996
19. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48: 1008-1016, 2005
20. Parving HH, de Zeeuw D, Cooper ME, Liu N, Lunceford J, Shanhifar S, Wong P, Lyle P, Brenner BM: Influence of angiotensin-converting enzyme insertion/deletion polymorphism on renal outcomes and death in relation to losartan treatment in patients with type 2 diabetes and nephropathy [Abstract]. J Am Soc Nephrol 17: 100A, 2006
21. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003